ASAHI INTECC is a medical device company focused on delivering clinically unique devices used in vascular procedures by interventional cardiologists, interventional radiologists, vascular surgeons, and neurovascular surgeons. We leverage our four core technologies to develop device-based solutions targeted to specific niches where we can achieve a leading market position.
SheathLess Eaucath PTCA Guiding Catheter
Asahi’s proprietary Sheathless Technology allows you to perform a full range of procedures – from the simplest to the most complex – via the radial approach.
Sheathless Technology = More Choices: Large inner lumen expands treatment options with all the benefits of TRI.
Hydrophilic Coating: Designed to ease catheter insertion, manipulation, and reduce the incidence of spasm.
ASAHI Braiding: Two unique braiding patterns provide optimal torque, kink resistance, flexibility, and support.
Indication for use
SheathLess Eaucath Coronary Guide Catheter is intended to provide a pathway through which therapeutic and diagnostic devices are introduced. The guide catheter is intended to be used in the coronary vascular system.
CellAegis Devices is a medical device company based in Toronto, Canada. We are commercializing the autoRIC® Device, a proprietary, non-invasive medical device that delivers a protective therapy called Remote Ischemic Conditioning (RIC). The autoRIC® Device is patent protected and is approved by Health Canada and has CE Mark for sale in the European Union.
The approved Intended Use is: ‘The autoRIC Device is intended to provide remote ischemic conditioning to adult patients over 18 years of age undergoing cardiothoracic surgery or interventional cardiothoracic procedures or patients with evolving myocardial infarction. The autoRIC Device is intended for use in the hospital, ambulance or in the home settings as directed by a healthcare professional.’
The autoRIC Device
In clinical trials, RIC has been shown effective in protecting multiple organs against Ischemia Reperfusion Injury (IRI), particularly in the heart where infarct size is decreased up to 50%. The therapy has clinically significant short-term benefit, reducing 30 day readmission rates and hospital complications, as well as long-term benefit in morbidity and mortality, where readmissions, adverse events and mortality are reduced 35-70% over the 4 to 6 year period.
Value in Automated RIC
The CellAegis autoRIC® Device is a new, portable, automated and non-invasive device that provides ‘point of care’ delivery of Remote Ischemic Conditioning (RIC) that is adjunct to standard of care.
The CellAegis autoRIC® Device is highly portable and resource-efficient, delivering four cycles of simple-to-administer treatment by way of a simple single start button. The total RIC treatment is less than 40 minutes, with minimal impact on valuable healthcare resources. Device operation is compatible with current standard-of-care treatments. Automated RIC delivery is safe accurate, reliable, and cost-effective.
Automating RIC Across the Spectrum of Care
CellAegis’ autoRIC® Device can be used across the spectrum of care: RIC has proven efficacy in acute care settings, including treatment of patients in the ambulance or emergency room, or before cardiac procedures (surgery or other cardiac interventions). The simple to use autoRIC® Device also allows for patient administered treatment in the home for chronic disease treatment.
The company designs and produces radiation protection equipment designed for the medical world, research, industry and nuclear protection. With over 40 years of innovation, and supported by its scientific college of international experts, it has become the world leader in innovation in its sectors of activity, exporting its technologies throughout the world. LemerPax is very actively involved in the optimization of the protection of operators exposed to ionizing radiation.
To overcome constraints in Electrophysiology – in collaboration with eminent practitioners as Professor Michel Haïssaguerre / Hôpital Cardiologique Haut-Lévêque / University Bordeaux 2 / Institut hospitalo-universitaire LIRYC / Bordeaux-Pessac, France / Lemer Pax has developed a whole range of mobile radiation protection cabins. First models have been developed for procedures like Atrial Fibrillation ablation (AF) followed by systems for interventional cardiology, radiology, neurology and endovascular surgery.
Z-Medica is the home of the innovative blood clotting technology behind QuikClot® family of products for hemostasis. Z-Medica was founded in 2002 by Francis X. Hursey, a veteran of the Apollo Project Breathing Air Team.
Z-Medica manufactures the QuikClot® family of hemostatic products. QuikClot promotes clotting within minutes from application and is safe, effective and easy to use. QuikClot is designed for use by Healthcare Professionals, First Responders, Law Enforcement Officers, Consumers and the Military. QuikClot Combat Gauze® is the only hemostatic agent recommended by the Department of Defense for all branches of the U.S. Military for severe hemorrhage on the battlefield.
QuikClot products are now in their third generation and are impregnated with a mineral called kaolin that has been clinically shown to accelerate the body’s natural coagulation cascade. Kaolin is a naturally-occurring, inorganic mineral that does not contain any botanicals, biological material or shellfish products and does not cause any exothermic reaction or vascular complications. QuikClot products are credited with helping thousands of people survive traumatic blood loss every year.
It has been known for many years that the intrinsic blood clotting pathway is inititiated by negatively charged surfaces such as kaolin or glass. Kaolin is utilized routinely in reagents that are used to assay blood clotting times by clinical laboratories that follow procedures that are published by the College of American Pathologists (CAP).
Kaolin is an inert mineral and it promotes clotting by two main modes of action:
• Kaolin promotes the activation of Factor XII (FXII) in the presence of kallikrein and high molecular weight kininogen. Activated FXII initiates the intrinsic clotting pathway via the activation of Factor XI. Activated FXI continues the coagulation pathway that ends with the formation of a fibrin clot.
• Kaolin promotes the activation of platelet-associated FXI and it is a distinct and separate molecule from plasma FXI. Activated platelet-associated FXI initiates the intrinsic clotting pathway in normal and FXII deficient patients.
Blood Coagulation Pathways
QuikClot® hemostatic devices can help patients survive traumatic blood loss.
The unpredictable nature of patient care requires a reliable way to achieve hemostasis.
QuikClot® EMS hemostatic devices are a life-saving technology that every first responder needs.
Trauma is a major cause of death and disability and the second most expensive healthcare problem in the United States. Approximately 40% of trauma-related deaths are due to bleeding or its consequences, establishing hemorrhage as the most common cause of preventable death in trauma.1
1. Curry N, Hopewell S, Doree C, Hyde C, Brohi K, Stanworth S. The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Crit Care . 2011;15(2):R92.
QuikClot® hemostatic devices help first responders provide life-saving assistance until additional medical personnel arrive.
Used by many municipalities across the United States, QuikClot® hemostatic devices put life-saving technology into the hands of trained law enforcement officials.
QuikClot Combat Gauze® is the hemostatic dressing of choice stated in the 2014 CoTCCC Guidelines.1
After extensive testing by the United States Army Institute for Surgical Research (USAISR) and the Naval Medical Research Center (NMRC), the Committee on Tactical Combat Casualty Care (CoTCCC) chose QuikClot Combat Gauze®.
1. Tactical Combat Casualty Care Guidelines 2 June 2014. http://www.usaisr.amedd.army.mil/pdfs/TCCC_Guidelines_140602.pdf. Accessed March 25, 2015.